Cantor Fitzgerald upgraded uniQure N.V. (NASDAQ:QURE) to an Overweight rating with a $61.00 price target. The U.S. Food and Drug Administration (FDA) provided a clear regulatory path for uniQ...
Investment firm Citigroup downgraded Devon En...
Corporate activities such as financing, acqui...
Liberty Latin America Ltd. (NASDAQ: LILAK) and Liberty Latin America Ltd. (NASDAQ: LILA) experienced significant stock price declines following a special dividend distribution. U-BX Technology Ltd. (
IonQ is recognized as a leader in the competitive quantum computing sector, despite rivals like Quantinuum. Analyst firm Vertical Research maintains an "Outperform" rating for IonQ, citing its strong
Alnylam Pharmaceuticals demonstrates robust financial efficiency, with its Return on Invested Capital (ROIC) significantly exceeding its Weighted Average Cost of Capital (WACC). The compariso
Zevra Therapeutics (NASDAQ: ZVRA) specializes in developing treatments for rare diseases, including idiopathic hypersomnia and stimulant use disorder. The company's current Return on Invested
Spectrum Brands Holdings (NYSE:SPB) exhibits strong business fundamentals, evidenced by its diverse consumer product portfolio and a high Piotroski Score of 8. The SPB stock performance has seen a 10
Accenture plc (NYSE: ACN) Faces Shifting Analyst Sentiment Ahead of Q3 Earnings Analyst sentiment for Accenture plc (NYSE: ACN) has shifted, with the average price target declining significantly over
